Newron plots phase 3 trial of schizophrenia drug after safet...

Newron Pharmaceuticals has clearance to press ahead with phase 3 development of its schizophrenia drug Evenamide after the FDA agreed a plan to address potential safety issues emerging from

Merck claims first-ever FDA approval for an Ebola vaccine

FDA takes another step to encourage copycat insulin products

The 4 biggest pharma market access stories of 2019

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive into the pharmaphorum archives to find out.

Epizyme's sarcoma drug tazemetostat faces key vote from FDA ...

Epizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed review from the agency’s own staffers.

Senate committee backs Hahn as new FDA Commissioner